Get alerted when Policy 4588458 changes without checking for updates manually.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
Prior authorization requirements for Actemra intravenous, Actemra ACTPEN, and Actemra subcutaneous products for FDA-approved indications and specified criteria-based uses.
Policy Summary
PayerCareSource
PolicyActemra intravenous and subcutaneous coverage
Policy CodePolicy 4588458
Change TypeNo material change
Effective DateOctober 1, 2026
Next Review DateN/A
Key ActionSubmit prior authorization for Actemra intravenous, Actemra ACTPEN, or Actemra subcutaneous products and include the diagnosis, concurrent medications, and previous drugs tried.
No material clinical or coverage changes in this revision.
3Actemra products affected
Plan yearCoverage approval duration
YesPrerequisite therapy required
NoPart B prerequisite
Product-Specific Coverage Criteria
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
Rheumatoid arthritis initial therapy
Covered when either pathway is met.
Rheumatoid arthritis: Patient has rheumatoid arthritis and has tried one qualifying drug (Enbrel, a preferred adalimumab product, Rinvoq, or tofacitinib/tofacitinib XR; specified alternative biologics or a non-preferred adalimumab product also count), or has heart failure or a previously treated lymphoproliferative disorder.
PJIA initial therapy
Covered when either pathway is met.
Polyarticular juvenile idiopathic arthritis: Patient has PJIA and has tried one qualifying drug (Enbrel, Rinvoq, tofacitinib, or a preferred adalimumab product; specified alternative therapies or a non-preferred adalimumab product also count), or has heart failure or a previously treated lymphoproliferative disorder.
Other covered indications
Covered when the applicable indication criteria are met.
Other covered indications: Systemic-onset JIA; giant cell arteritis with a systemic corticosteroid tried, currently used, or contraindicated; or interstitial lung disease associated with systemic sclerosis with elevated acute phase reactants and diagnosis confirmed by high-resolution computed tomography.
Alunbrig initial therapy
Covered when the applicable indication pathway is met.
Alunbrig indications: ALK-positive advanced or metastatic NSCLC detected by an approved test; ALK-positive advanced, recurrent, or metastatic inflammatory myofibroblastic tumor or inoperable tumor; or ALK-positive anaplastic large cell lymphoma.
Anktiva initial therapy
All criteria must be met.
Anktiva: High-risk BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, and use in combination with BCG.
Arcalyst initial therapy
Meet the applicable indication pathway.
Arcalyst initial indications: DIRA requires weight at least 10 kg, biallelic pathogenic IL1RN variants, and clinical benefit with anakinra; recurrent pericarditis must be recurrent; or CAPS meets applicable coverage requirements.
Arcalyst continuation therapy
Continuation requires response.
Arcalyst continuation: Patient had a positive response to Arcalyst therapy.
Arikayce initial therapy
All criteria must be met.
Initial MAC lung disease: Positive MAC sputum culture, amikacin-susceptible isolate, and use with a background multidrug regimen.
Arikayce continuation therapy
All criteria must be met, including one culture-status alternative.
Continuation MAC lung disease: Arikayce is used with a background multidrug regimen and the patient either has not achieved negative MAC sputum cultures or achieved negative cultures for less than 12 months.
Aubagio and Avonex coverage
Coverage is for relapsing multiple sclerosis.
Aubagio and Avonex: Patient has relapsing MS, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease; concurrent use with another MS disease-modifying agent is excluded.
Augtyro coverage
Meet one applicable indication pathway.
Augtyro indications: Locally advanced or metastatic ROS1-positive NSCLC confirmed by an approved test; locally advanced, metastatic, or severely morbid-to-resect NTRK fusion-positive solid tumor; or NTRK fusion-positive pediatric diffuse high-grade glioma used as adjuvant therapy or for recurrent/progressive disease.
Avmapki-Fakzynja coverage
All criteria must be met.
Avmapki-Fakzynja: Recurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancer; KRAS mutation; and at least one prior systemic therapy.
Avmapki-fakzynja
All criteria must be met.
Avmapki-fakzynja: Recurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancer with a KRAS mutation and at least one prior systemic therapy.
Ayvakit
Meet one applicable disease pathway.
Ayvakit: GIST with PDGFRA exon 18 mutation or after two listed prior therapies; PDGFRA D842V-positive myeloid/lymphoid neoplasm with eosinophilia; or systemic mastocytosis meeting the platelet-count and subtype criteria.Systemic mastocytosis platelet count >=50,000/mcL
Balversa
Meet the applicable disease and molecular criteria.
Balversa: Susceptible FGFR3 alteration with progression during or after applicable prior therapy; locally advanced, recurrent, or metastatic FGFR-altered pancreatic adenocarcinoma used as subsequent single-agent therapy; or metastatic FGFR-altered NSCLC.
Benlysta and Benlysta IV
Meet the applicable lupus indication criteria.
Benlysta and Benlysta IV: Biopsy-confirmed lupus nephritis with concurrent immunosuppressive therapy, or autoantibody-positive SLE with concurrent standard therapy. Initial age is at least 5 years; lupus nephritis continuation also requires response.
Bexarotene topical
Covered for the specified lymphoma indications.
Topical bexarotene: Cutaneous T-cell lymphoma with cutaneous manifestations or lesions; smoldering symptomatic adult T-cell leukemia/lymphoma treated first line; or primary cutaneous marginal-zone or follicle-center B-cell lymphoma treated with skin-directed therapy.
Bizengri
Meet one applicable cancer pathway.
Bizengri: Advanced, unresectable, or metastatic NRG1 gene-fusion-positive cholangiocarcinoma; or corresponding NRG1-positive NSCLC or pancreatic adenocarcinoma after at least one systemic regimen.
Blenrep
All criteria must be met.
Blenrep: At least one prior proteasome inhibitor and one prior immunomodulatory drug, with planned combination use with bortezomib and dexamethasone.Age >=18 years
Boniva Injection
Postmenopausal osteoporosis plus at least one qualifying criterion is required.
Boniva Injection: T-score at or below -2.5; osteoporotic or fragility fracture; osteopenia with high fracture risk and inadequate oral bisphosphonate response after 12 months; fracture or intolerance on oral therapy; inability to take oral therapy; or prior IV bisphosphonate.
Bosentan or Ambrisentan
Meet the applicable PAH or CTEPH pathway.
Bosentan or Ambrisentan: WHO Group 1 PAH confirmed by right-heart catheterization; or CTEPH treated with bosentan after an Adempas trial, Adempas contraindication, or current bosentan therapy.
Bosulif
Meet one applicable hematologic malignancy pathway.
Bosulif: Philadelphia chromosome-positive or BCR::ABL1-positive CML; Philadelphia chromosome-positive ALL after at least one other TKI; or qualifying myeloid/lymphoid neoplasm with eosinophilia.
Bosentan/ambrisentan
Meet the applicable diagnosis, testing, prescriber, and prerequisite criteria.
Bosentan/ambrisentan: WHO Group 1 PAH confirmed by right-heart catheterization with cardiologist or pulmonologist involvement, or CTEPH treated with bosentan after the specified Adempas prerequisite or current bosentan use.
Bosulif
Meet the applicable diagnosis and age or prior-treatment criteria.
Bosulif: CML with Philadelphia chromosome-positive or BCR::ABL1-positive disease; Ph-positive ALL after another TKI; or myeloid/lymphoid neoplasm with eosinophilia.Age >=15 years generally; >=18 years for myeloid/lymphoid neoplasms with eosinophilia
Braftovi
Document diagnosis, mutation status, and required regimen.
Braftovi: BRAF V600-mutated advanced melanoma; BRAF V600E colorectal or rectal cancer with the required combination regimen; BRAF V600E recurrent/advanced/metastatic NSCLC with Mektovi; or BRAF V600E advanced/metastatic appendiceal adenocarcinoma with Erbitux or Vectibix.Age >=18 years
Briumvi
All criteria must be met.
Briumvi: Relapsing multiple sclerosis, age at least 18 years, neurologist or MS specialist involvement, and no concurrent MS disease-modifying agent.
Brukinsa
Meet the malignancy-specific criteria.
Brukinsa: Covered follicular, CLL/SLL, mantle-cell, marginal-zone, Waldenstrom/lymphoplasmacytic, hairy-cell, or primary CNS lymphoma pathway with the required prior systemic therapy or combination treatment.Age >=18 years
Cinryze
Meet the applicable HAE diagnostic or response criteria.
Cinryze: Type I or II HAE with baseline functional C1-INH below 50% of normal and low C4; established type I or II HAE with favorable response; or HAE with normal C1-INH.
Cablivi
All criteria must be met.
Cablivi: Acquired TTP treatment was initiated inpatient with plasma exchange; patient is receiving at least one immunosuppressive therapy; and prior Cablivi exposure was no more than two courses.Age >=12 years
Cabometyx
Meet the indication-specific criteria.
Cabometyx: Qualifying renal, hepatic, bone, thyroid, endometrial, GIST, RET-positive NSCLC, or well-differentiated pancreatic or extra-pancreatic neuroendocrine tumor pathway with required disease status, molecular findings, and prior therapy.
Calquence
Meet the applicable malignancy and treatment-history criteria.
Calquence: CLL/SLL; mantle-cell lymphoma with the required prior regimen, ineligibility, or rituximab combination; marginal-zone lymphoma after one systemic regimen; or Waldenstrom/lymphoplasmacytic lymphoma after one systemic regimen.
Camzyos initial and continuation therapy
Initial and continuation criteria must be met as applicable.
Initial therapy: Symptomatic obstructive HCM; NYHA class II or III heart failure; specified LV hypertrophy; and peak LV outflow tract gradient at least 50 mmHg.
Continuation therapy: At least 8 months established therapy, current LVEF at least 50%, and objective benefit or stabilization/improvement of an HCM symptom.
Caprelsa
Covered for FDA-approved and specified medically accepted indications.
Caprelsa: A qualifying FDA-approved or medically accepted indication, including differentiated thyroid cancer such as papillary, follicular, or oncocytic thyroid cancer.
Deferasirox initial and continuation therapy
Meet the applicable initial or continuation criteria.
Deferasirox: Qualifying iron-overload condition with ferritin greater than 1,000 mcg/L before therapy; or non-transfusion-dependent thalassemia with ferritin greater than 300 mcg/L. Continuation requires physician-confirmed benefit.
Deferiprone iron overload
Coverage is for qualifying chronic transfusion-related iron overload.
Deferiprone: Chronic transfusion-related iron overload due to thalassemia syndrome, sickle cell disease, or another anemia. Continuation requires documented benefit.
Diacomit Dravet syndrome
Initial or continuation criteria must be met.
Initial therapy: Age at least 6 months, Dravet syndrome, and concomitant clobazam or inability to take clobazam because of adverse events.
Continuation therapy: Patient is responding to Diacomit therapy.
Doptelet thrombocytopenia
Coverage depends on indication and treatment phase.
Chronic liver disease thrombocytopenia: Doptelet tablets, platelet count below 50 x 10^9/L, bleeding risk, and prior therapy failure or splenectomy.
Chronic ITP continuation: Beneficial clinical response and ongoing risk of bleeding complications.
Droxidopa NOH
All criteria must be met.
Neurogenic orthostatic hypotension: Age at least 18 years and symptomatic NOH due to primary autonomic failure, dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy.
Dupixent asthma initial therapy
All criteria must be met, including one uncontrolled-asthma criterion.
Asthma initial therapy: Eosinophils at least 150 cells/µL or oral corticosteroid-dependent asthma; ICS plus at least one additional controller; and uncontrolled asthma demonstrated by qualifying exacerbation, hospitalization, lung-function, or corticosteroid-taper criteria.
Dupixent COPD initial therapy
All criteria must be met.
COPD initial therapy: Eosinophils at least 300 cells/µL; at least 3 months of combination therapy with at least two of LAMA, LABA, or ICS; and qualifying exacerbations or hospitalization in the prior 12 months.
Dupixent continuation therapy
Continuation requires prior treatment and an indication-specific beneficial response.
Dupixent continuation: Patient completed the applicable prior Dupixent period and has the required indication-specific response and concurrent therapy; most listed indications require at least 6 months of prior therapy.
Asthma
All criteria must be met.
Asthma: Eosinophils at least 150 cells/µL or oral corticosteroid-dependent asthma; ICS plus another controller; and at least one qualifying uncontrolled-asthma criterion.
COPD
All criteria must be met.
COPD: Eosinophils at least 300 cells/µL; at least 3 months of at least two of LAMA, LABA, or ICS; and qualifying exacerbations or hospitalization in the prior year.
Respiratory and allergic indications
Meet the applicable indication-specific criteria.
Respiratory and allergic indications: CRSwNP, eosinophilic esophagitis, or allergic fungal rhinosinusitis meeting the documented symptom, treatment, biopsy, imaging, weight, and surgical criteria.
Dermatologic indications
Meet the applicable disease-duration or treatment-history criterion.
Dermatologic indications: Prurigo nodularis with pruritus for at least 6 weeks, or chronic spontaneous urticaria lasting more than 6 weeks despite a non-sedating H1 antihistamine.
Elahere
All criteria must be met.
Elahere: Age at least 18 years, ovarian, fallopian tube, or primary peritoneal cancer diagnosis, and oncology prescriber or consultant.
Elaprase
One diagnostic confirmation pathway must be met.
Elaprase: Deficient iduronate-2-sulfatase activity demonstrated by laboratory testing or a qualifying iduronate-2-sulfatase molecular genetic finding.
Elrexfio
All criteria must be met.
Elrexfio: Multiple myeloma after at least four systemic regimens, including at least one drug from each required prior-treatment class.At least 4 systemic regimens; age >=18 years
Emgality
Meet the applicable headache criteria.
Emgality: Migraine prevention with at least 4 migraine days per month and, for continuation, significant clinical benefit; or episodic cluster headache with one headache every other day to eight headaches per day.
Emrelis
All criteria must be met.
Non-squamous NSCLC: Locally advanced or metastatic non-squamous NSCLC; c-Met overexpression of at least 50% of tumor cells with strong 3+ staining by an approved test; and at least one prior systemic therapy.
Epidiolex
Initial or continuation criteria must be met.
Epidiolex: For the applicable seizure disorder, required prior or concomitant antiseizure therapy has been tried; continuation requires response.
Epkinly
At least one systemic therapy line is required.
Epkinly: Diffuse large B-cell, classic follicular, HIV-related B-cell lymphoma, or post-transplant lymphoproliferative disorder after one or more lines of systemic therapy.
Epoetin alfa
Meet the indication-specific anemia criteria.
Epoetin alfa: Qualifying CKD, chemotherapy-associated, HIV/zidovudine, surgical, MDS, or myelofibrosis anemia with the applicable hemoglobin or erythropoietin threshold and treatment status.
Erivedge
Meet one qualifying pathway.
Erivedge: Locally advanced BCC recurrent after surgery/radiation or unsuitable for both; metastatic or diffuse BCC; or medulloblastoma after chemotherapy with a sonic hedgehog pathway mutation.
Epoetin alfa initial and continuation therapy
Initial or continuation criteria must be met.
Epoetin alfa: Initial therapy: Hb below 10 g/dL or serum erythropoietin at or below 500 mU/mL. Continuation: currently receiving an ESA and Hb at or below 12 g/dL.
Erivedge coverage criteria
Covered for qualifying indications.
Erivedge: Qualifying locally advanced, metastatic, or diffuse basal cell carcinoma, or medulloblastoma meeting prior chemotherapy and sonic hedgehog mutation criteria.
Erleada coverage criteria
All FDA-approved indications require androgen deprivation.
Erleada: Used with a GnRH analog or after bilateral orchiectomy.
Erlotinib coverage criteria
Meet one applicable indication pathway.
Erlotinib: EGFR mutation-positive advanced/metastatic NSCLC; qualifying RCC with bevacizumab; chordoma after prior therapy; pancreatic cancer with gemcitabine; or advanced, recurrent, or metastatic vulvar cancer.
Everolimus coverage criteria
Meet the indication-specific requirements.
Everolimus: Qualifying breast cancer, RCC, TSC-associated, thyroid, thymic, hematologic, neuroendocrine, sarcoma, meningioma, or other listed indication with required biomarker, combination, and prior-treatment criteria.
Fabrazyme coverage criteria
One diagnostic confirmation pathway must be met.
Fabrazyme: Deficient alpha-galactosidase A activity in leukocytes or fibroblasts, or a pathogenic galactosidase alpha molecular variant.
Fasenra initial therapy
All criteria for the applicable indication must be met.
Fasenra: Asthma with eosinophils at least 150 cells/µL, ICS plus another controller, and uncontrolled disease; active non-severe EGPA with eosinophils at least 150 cells/µL; or HES with FIP1L1-PDGFR-alpha-negative disease, no non-hematologic secondary cause, and eosinophils at least 1,000 cells/µL.
Fintepla initial and continuation therapy
Meet the applicable syndrome and antiseizure-treatment criteria.
Fintepla: Dravet syndrome with at least two other antiseizure drugs or Epidiolex, clobazam, or Diacomit; Lennox-Gastaut syndrome with at least two other antiseizure drugs; continuation requires response.
Fotivda coverage criteria
All criteria must be met.
Fotivda: Relapsed or stage IV renal cell carcinoma after at least two prior systemic regimens.
Fruzaqla coverage criteria
All criteria must be met.
Fruzaqla: Advanced or metastatic colon, rectal, or appendiceal cancer; applicable pMMR/MSS or checkpoint-inhibitor and dMMR/MSI-H or POLE/POLD1 pathway; prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy plus anti-VEGF therapy; and any required RAS wild-type pathway treatment.
Testosterone initial and continuation therapy
Initial and continuation criteria apply to injectable testosterone.
Initial hypogonadism therapy: Persistent androgen-deficiency signs and symptoms, two morning testosterone measurements on separate days, and both low by laboratory reference values.
Continuation hypogonadism therapy: Persistent androgen-deficiency signs and symptoms and at least one low pretreatment testosterone level.
Inlexzo
All criteria must be met.
Inlexzo: BCG-unresponsive disease, age at least 18 years, and oncologist or urologist prescriber or consultant.
Inluriyo breast cancer
All criteria must be met.
Inluriyo: Recurrent, advanced, or metastatic HR-positive, HER2-negative, ESR1-mutated breast cancer; at least one prior endocrine therapy; and applicable postmenopausal, male, or ovarian-suppression/ablation status.
Inlyta
Meet one applicable indication pathway.
Inlyta: Radioactive-iodine-refractory papillary or follicular thyroid carcinoma; oncocytic/Hurthle cell carcinoma; alveolar soft-part sarcoma with Keytruda; or thymic carcinoma after chemotherapy with Bavencio.
Inpefa
Meet one applicable indication.
Inpefa: Heart failure; or type 2 diabetes with chronic kidney disease and at least one cardiovascular risk factor.
Inqovi
Both criteria must be met.
Inqovi: AML and age at least 75 years or comorbidities precluding intensive induction therapy; use in combination with Venclexta.
Inrebic
A qualifying disease-related symptom is required.
Inrebic: Covered myeloproliferative neoplasm indication and at least one disease-related symptom, such as fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, or leukocytosis.
Itovebi breast cancer
All criteria must be met.
Itovebi: Applicable menopausal or ovarian-suppression status; locally advanced or metastatic HR-positive, HER2-negative breast cancer; approved-test-detected PIK3CA mutation; progression or recurrence after adjuvant endocrine therapy; and combination use with palbociclib.
Oral ivermectin
Meet one qualifying infection or scabies circumstance.
Oral ivermectin: Head, body, or pubic lice; or classic, treatment-resistant, crusted, topical-treatment-intolerant, or tablet-treated scabies.
IVIG
Coverage is subject to CMS benefit determination.
IVIG: Use is for a medically accepted indication, with Part B versus Part D determination under CMS guidance when primary immunodeficiency is treated at home.
Iwilfin
All criteria must be met.
Iwilfin: High-risk neuroblastoma, use to reduce relapse risk, and at least partial response to prior multimodality therapy including anti-GD2 immunotherapy.
Jakafi and Jakafi XR
Meet one applicable indication pathway.
Jakafi and Jakafi XR: Covered ALL, GVHD, atypical CML, CMML-2, essential thrombocythemia, myeloid/lymphoid neoplasm, or T-cell lymphoma pathway with the required mutation, symptoms, combination, or prior therapy.
Jaypirca
Meet the applicable prior-treatment pathway.
Jaypirca: Mantle-cell lymphoma after systemic chemotherapy or ineligibility plus prior BTK inhibitor; CLL/SLL after prior BTK inhibitor; or Richter transformation after chemotherapy or ineligibility with specified prior therapy.
Jemperli
Meet one applicable malignancy or biomarker pathway.
Jemperli: Recurrent/advanced/metastatic endometrial cancer; dMMR/MSI-H solid tumor; qualifying dMMR/MSI-H or POLE/POLD1 small-bowel, colorectal, rectal, or appendiceal cancer; or qualifying single-agent anal carcinoma.
Authorization, Documentation, and Denial Rules
Prior Authorization
Prior Authorization and Required Medical Information
Prior authorization is required for ACTEMRA intravenous and subcutaneous products. Submit the diagnosis, concurrent medications, previous therapies tried, applicable age and prescriber information, and indication-specific clinical records.
Do not use concurrently with a biologic DMARD or targeted synthetic DMARD.
Do not approve ACTEMRA for treatment of COVID-19 in hospitalized patients under the non-D benefit.
Initial RA, PJIA, SJIA, or GCA therapy requires prescribing by or consultation with a rheumatologist; interstitial-lung-disease therapy requires pulmonology or rheumatology involvement.
RA and PJIA generally require a qualifying prior therapy or an exception such as heart failure or a previously treated lymphoproliferative disorder.
GCA requires prior systemic corticosteroid therapy or documented corticosteroid contraindication.
Authorization is generally through the end of the plan year.
Documentation Required
Required Medical Information and Diagnosis Documentation
Submit complete diagnosis and supporting clinical documentation for all requested drugs, including laboratory results, pathology, genetic or molecular testing, prior-treatment history, concurrent medications, response to therapy, and benefit classification when applicable.
Documentation must support the requested indication, age, prescriber specialty, prerequisite therapy, and continuation response.
Part B versus Part D benefit determination is made during prior-authorization review when specified by the policy.
Requests lacking required medical information or documentation of the applicable criteria may be denied.
Documentation Required
Prolastin-C Documentation
Prolastin-C requires documentation of alpha1-antitrypsin deficiency with emphysema or COPD, including baseline pretreatment clinical information. The patient must be 18 years or older; authorization is generally for one year.
Submit diagnosis documentation and the baseline pretreatment information requested by the plan.
Prior Authorization
Alunbrig ALK Status and Prerequisite Therapy
Alunbrig requires prior authorization and documentation of ALK status. Coverage requires disease-specific documentation and, for newly treated advanced or metastatic NSCLC, a prior trial of Alecensa, Ensacove, or Lorbrena.
Document ALK rearrangement or fusion-positive disease using an approved test.
For IMT, document ALK-positive advanced, recurrent, metastatic, or inoperable disease.
For peripheral T-cell lymphoma, document ALK-positive anaplastic large-cell lymphoma.
Submit prior ALK-inhibitor therapy when required.
Prior Authorization
Anktiva Diagnosis Documentation
Anktiva requires prior authorization for adults with high-risk BCG-unresponsive non-muscle-invasive bladder cancer. Submit diagnosis documentation confirming carcinoma in situ and use in combination with BCG.
Initial therapy requires all of the following: high-risk BCG-unresponsive disease, carcinoma in situ, and combination use with BCG.
Initial requests are generally authorized for six months and maintenance requests for three months.
Prescribing or consultation by an oncologist or urologist is required.
Prior Authorization
IV Antibiotic Prior Authorization
Prior authorization is required for the listed intravenous antibiotics. Submit the diagnosis and clinical rationale for the requested agent; authorization is generally limited to three months.
Affected products include the listed intravenous antibacterial agents such as levofloxacin, linezolid, meropenem, metronidazole, nafcillin, oxacillin, penicillin G, streptomycin, trimethoprim-sulfamethoxazole, ceftazidime, ceftaroline, tigecycline, tobramycin, and telavancin.
Document the infection being treated and the requested treatment course.
Prior Authorization
IV Antifungal Prior Authorization
Prior authorization is required for intravenous antifungal therapy. Submit diagnosis documentation and the requested treatment course; authorization is generally limited to three months.
Affected products include intravenous voriconazole and voriconazole-HBCD.
Document the fungal infection and medical necessity for intravenous treatment.
Denial Risk
Arcalyst Exclusions and DIRA Requirements
Arcalyst requires prior authorization and must not be used concurrently with biologic therapy. Submit indication-specific documentation and the required specialist information.
For DIRA, document weight of at least 10 kg, biallelic pathogenic IL1RN variants on genetic testing, and clinical benefit from subcutaneous anakinra.
For recurrent pericarditis, document recurrent disease; cardiology or rheumatology involvement is required.
Continuation requires a positive response to therapy.
For CAPS, initial therapy is restricted to patients at least 12 years old and requires the applicable specialist.
Prior Authorization
Arikayce Diagnosis and Treatment History
Arikayce requires documentation of MAC lung disease and treatment history. Initial therapy requires positive MAC sputum culture, an amikacin-susceptible isolate, and combination use with a background multidrug regimen.
Document the diagnosis, positive sputum culture, susceptibility results, and prior medication history.
The background regimen should include a macrolide, ethambutol, and a rifamycin unless the record supports another regimen.
Continuation requires combination use with the background regimen and either persistently negative cultures not yet achieved or negative cultures for less than 12 months.
Initial therapy is for adults and requires pulmonology, infectious-disease, or MAC-lung specialist involvement.
Unsupported block type: prior_auth
Unsupported block type: prior_auth
Unsupported block type: prior_auth
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: prior_auth
Prior Authorization
Additional Indication and Prerequisite Rules
The following additional prior-authorization rules apply: age, specialist, indication, prior-treatment, combination-therapy, exclusion, and benefit-classification criteria must be satisfied and documented before approval.
Alosetron: patient must be 18 years or older.
Asparlas: patient must be 1 month through 21 years of age.
Augtyro: submit diagnosis and ROS1 or NTRK molecular results and document disease extent.
Avmapki-Fakzynja: document recurrent low-grade serous ovarian, fallopian-tube, or primary-peritoneal cancer, KRAS mutation, and prior systemic therapy.
Avonex and Betaseron/Extavia: document relapsing MS and no concurrent MS disease-modifying therapy.
Ayvakit: document the qualifying PDGFRA mutation, GIST prior therapies, or systemic-mastocytosis criteria.
Balversa: document FGFR alteration, disease, and required prior platinum, chemotherapy, checkpoint inhibitor, or combination therapy.
Blenrep: document prior proteasome-inhibitor and immunomodulatory-drug classes and required combination therapy.
Droxidopa: document symptomatic neurogenic orthostatic hypotension, qualifying autonomic disorder, and prior medication history.
Erivedge: document qualifying basal-cell or CNS cancer, prior chemotherapy, prior local therapy or ineligibility for surgery/radiation, and applicable mutation.
Erleada: document concurrent GnRH-analog therapy or bilateral orchiectomy.
Everolimus: document prior endocrine or systemic therapy, required combination, and absence of progression on everolimus.
Unsupported block type: denial_risk
Note
Specialty Drug Authorization Duration
Specialty-drug authorization is generally limited to the duration stated in the product criteria, commonly one year, with shorter initial or induction periods for selected products. Submit continuation documentation before expiration.
Document beneficial clinical response for continuation therapy.
Initial and continuation durations may differ for Anktiva, Arcalyst, Camzyos, Dupixent, Fasenra, Doptelet, and other products.
Authorization does not replace required medical-necessity review or benefit determination.
Initial Therapy Decision Criteria
Rheumatoid arthritis initial therapy
Initial therapy is covered when either pathway is met.
Rheumatoid arthritis: Tried one qualifying drug: Enbrel, preferred adalimumab product, Rinvoq, or tofacitinib/tofacitinib XR; specified alternatives also count. Alternatively, the patient has heart failure or a previously treated lymphoproliferative disorder.
PJIA initial therapy
Initial therapy is covered when either pathway is met.
PJIA: Tried one qualifying drug: Enbrel, Rinvoq, tofacitinib, or preferred adalimumab product; specified alternatives also count. Alternatively, the patient has heart failure or a previously treated lymphoproliferative disorder.
Other initial therapy criteria
Meet the applicable indication criteria.
Other initial indications: Systemic-onset JIA; giant cell arteritis with systemic corticosteroid trial, current use, or contraindication; or systemic-sclerosis-associated interstitial lung disease with elevated acute phase reactants and high-resolution CT confirmation.
Arcalyst initial therapy
Meet the applicable indication pathway.
Arcalyst: DIRA with weight at least 10 kg, biallelic pathogenic IL1RN variants, and anakinra benefit; recurrent pericarditis; or CAPS.
Arikayce initial therapy
All criteria must be met.
Arikayce: Positive MAC sputum culture, amikacin-susceptible isolate, and use with a background multidrug regimen.
Avmapki-fakzynja
All criteria must be met.
Avmapki-fakzynja: Recurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancer, KRAS mutation, and at least one prior systemic therapy.
Avonex
All criteria must be met.
Avonex: Relapsing MS and neurologist or MS specialist prescribing or consultation.
Ayvakit
Meet the applicable disease criteria.
Ayvakit: Qualifying GIST, PDGFRA D842V-positive myeloid/lymphoid neoplasm with eosinophilia, or systemic mastocytosis with platelet count at least 50,000/mcL and qualifying subtype.
Balversa
Meet the applicable disease and FGFR criteria.
Balversa: Qualifying FGFR-altered cancer with required disease stage, prior therapy, and treatment setting.
Benlysta
Meet the applicable SLE or lupus nephritis criteria.
Benlysta: Biopsy-confirmed lupus nephritis with concurrent immunosuppressive therapy, or autoantibody-positive SLE with concurrent standard therapy; initial age at least 5 years.
Besremi
All criteria must be met.
Besremi: Qualifying diagnosis, age at least 18 years, and oncologist or hematologist prescribing or consultation.
Bexarotene
A qualifying indication must be documented.
Bexarotene: FDA-approved indication or qualifying cutaneous or hematologic lymphoma indication; topical therapy must meet its disease-specific criteria.
Bizengri
Meet the applicable NRG1-positive cancer criteria.
Bizengri: Advanced, unresectable, or metastatic NRG1 gene-fusion-positive cholangiocarcinoma, NSCLC, or pancreatic adenocarcinoma; NSCLC and pancreatic cancer require at least one prior systemic regimen.
Blenrep
All criteria must be met.
Blenrep: Prior proteasome inhibitor and immunomodulatory drug exposure, and planned combination with bortezomib and dexamethasone.
Boniva Injection
Postmenopausal osteoporosis plus one qualifying criterion is required.
Boniva Injection: Postmenopausal osteoporosis and qualifying bone-density, fracture, prior-treatment, intolerance, or oral-therapy limitation criterion.
Bosentan or Ambrisentan
Meet the applicable PAH or CTEPH criteria.
Bosentan or Ambrisentan: WHO Group 1 PAH confirmed by right-heart catheterization, or CTEPH treated with bosentan after the specified Adempas prerequisite or current bosentan use.
Bosulif
Meet the applicable leukemia criteria.
Bosulif: Ph-positive/BCR::ABL1-positive CML; Ph-positive ALL after another TKI; or qualifying myeloid/lymphoid neoplasm with eosinophilia.
Bosentan/ambrisentan initial therapy
All applicable initial criteria must be met.
Bosentan/ambrisentan: WHO Group 1 PAH confirmed by right-heart catheterization and specialist prescribing or consultation; for CTEPH treated with bosentan, the required Adempas condition also applies.
Camzyos initial therapy
All criteria must be met.
Camzyos: Symptomatic obstructive HCM, NYHA class II or III heart failure, specified LV hypertrophy, and peak LV outflow tract gradient at least 50 mmHg.
Deferasirox initial therapy
Meet one initial pathway.
Deferasirox: Qualifying iron-overload condition with ferritin greater than 1,000 mcg/L, or non-transfusion-dependent thalassemia with ferritin greater than 300 mcg/L before therapy.
Diacomit initial therapy
All criteria must be met.
Diacomit: Age at least 6 months, Dravet syndrome, and clobazam use or inability to take clobazam because of adverse events.
Droxidopa initial therapy
All criteria must be met.
Droxidopa: Age at least 18 years and symptomatic NOH due to an eligible autonomic disorder.
Dupixent initial therapy
Meet one applicable indication pathway and its age and prescriber requirements.
Dupixent: Atopic dermatitis, asthma, COPD, CRSwNP, EoE, prurigo nodularis, CSU, bullous pemphigoid, or allergic fungal rhinosinusitis meeting the applicable criteria.
Initial specialty therapy
All applicable age, prescriber, and disease-specific criteria must be met.
Initial specialty therapy: Meet the clinical criteria, age restriction, and specialist prescriber or consultation requirement for the requested indication.
Enbrel
Prerequisite therapy is required except for GVHD.
Enbrel: For specified inflammatory indications, try a preferred or non-preferred adalimumab product; for Behcet disease, try a conventional therapy; GVHD does not require the stated prerequisite.
Endari and Ensacove
Meet the applicable age and prescriber criteria.
Endari: Age at least 5 years and sickle-cell specialist prescribing or consultation.
Ensacove: Age at least 18 years and an FDA-approved indication.
Fasenra initial therapy
Meet all criteria for the applicable indication.
Fasenra: Asthma with eosinophilia, ICS plus controller, and uncontrolled disease; active non-severe EGPA with eosinophilia; or qualifying HES.
Fintepla initial therapy
Meet the applicable syndrome and treatment-history criteria.
Fintepla: Dravet syndrome with qualifying antiseizure treatment or specified Epidiolex, clobazam, or Diacomit; or Lennox-Gastaut syndrome with at least two antiseizure drugs.
Testosterone initial therapy
All criteria must be met for hypogonadism initial therapy.
Testosterone: Persistent androgen-deficiency signs and symptoms, two morning testosterone measurements on separate days, and both low by laboratory reference values.
Continuation Therapy Decision Criteria
Arcalyst continuation
Continuation requires a positive response.
Arcalyst: Patient had a positive response to therapy.
Arikayce continuation
Both criteria must be met.
Arikayce is used with a background multidrug regimen and sputum cultures are either not negative or have been negative for less than 12 months.
Benlysta continuation
Both criteria must be met for lupus nephritis continuation.
Benlysta: Concurrent immunosuppressive regimen and response to Benlysta subcutaneous or intravenous therapy.
Benlysta IV continuation
Continuation criteria remain satisfied.
Benlysta IV: Applicable SLE or lupus nephritis continuation criteria remain satisfied.1 year continuation authorization
Cinryze continuation
Both criteria must be met.
Cinryze: Type I or II HAE and favorable clinical response to Cinryze prophylaxis compared with baseline.
Camzyos continuation
All criteria must be met.
Camzyos: At least 8 months established therapy; current or prior obstructive HCM symptoms and NYHA class II or III heart failure; current LVEF at least 50%; and objective benefit or symptom stabilization/improvement.
Deferasirox continuation
Continuation requires benefit.
Deferasirox: Prescribing physician confirms that the patient is benefiting from deferasirox.
Deferiprone continuation
Continuation requires benefit.
Deferiprone: Patient is benefiting from deferiprone therapy.
Diacomit continuation
Continuation requires response.
Diacomit: Patient is responding to Diacomit therapy.
Dupixent continuation
Continuation requires prior treatment and an indication-specific response.
Dupixent: Patient completed the applicable prior treatment period and has the required beneficial response and concurrent therapy for the indication.
Preceding specialty indications
Continuation is authorized when applicable criteria remain satisfied.
Preceding specialty indications: Patient continues to meet the applicable indication-specific criteria and demonstrates ongoing clinical benefit where required.
Continuation response
Continuation requires clinical benefit or response.
Continuation response: Emgality: significant clinical benefit such as fewer migraine days; or Epidiolex: response to therapy.
Fasenra continuation
Continuation is authorized for 12 months for asthma, HES, and EGPA.
Fasenra: Continuation criteria apply; detailed continuation criteria are not provided in the supplied policy window.
Fintepla continuation
Continuation requires response.
Fintepla: Patient is responding to therapy.
Testosterone continuation therapy
All continuation criteria must be met.
Testosterone: Persistent signs and symptoms of androgen deficiency and at least one low pretreatment serum testosterone level.
Prerequisite and Step-Therapy Requirements
Step
Product/indication
Prior-therapy requirement
1
Rheumatoid arthritis
Try Enbrel, a preferred adalimumab product, Rinvoq, or tofacitinib/tofacitinib XR. Trials of Cimzia, Kevzara, infliximab, golimumab, Orencia, or a non-preferred adalimumab product also count. Heart failure or a previously treated lymphoproliferative disorder is an alternative.
Step
Product/indication
Prior-therapy requirement
1
Polyarticular juvenile idiopathic arthritis
Try Enbrel, Rinvoq, tofacitinib, or a preferred adalimumab product. Trials of Kevzara, infliximab, Orencia, or a non-preferred adalimumab product also count. Heart failure or a previously treated lymphoproliferative disorder is an alternative.
Step
Product/indication
Prior-therapy requirement
1
Giant cell arteritis
Try or be currently taking a systemic corticosteroid, or document that corticosteroids are contraindicated.
Step
Product/indication
Prior-therapy requirement
1
Alunbrig — ALK-positive advanced or metastatic NSCLC; new to therapy
Try Alecensa, Ensacove, or Lorbrena before approval.
Step
Product/indication
Prior-therapy requirement
1
Arcalyst — DIRA
Prior anakinra subcutaneous injection therapy with documented clinical benefit.
Step
Product/indication
Prior-therapy requirement
1
Avmapki-Fakzynja — recurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancer
At least one prior systemic therapy; examples include paclitaxel, carboplatin, bevacizumab, letrozole, anastrozole, or exemestane.
Step
Product/indication
Prior-therapy requirement
1
Avmapki-fakzynja — recurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancer
Trial of at least one systemic therapy is required.
Step
Product/indication
Prior-therapy requirement
1
Ayvakit — GIST
Try two listed therapies: imatinib, sunitinib, dasatinib, regorafenib, or ripretinib, unless the tumor has a PDGFRA exon 18 mutation.
Step
Product/indication
Prior-therapy requirement
1
Blenrep
Prior exposure to at least one proteasome inhibitor and one immunomodulatory drug.
Step
Product/indication
Prior-therapy requirement
1
Bosentan — CTEPH
Try Adempas, have an Adempas contraindication, or be currently receiving bosentan for CTEPH.
Step
Product/indication
Prior-therapy requirement
1
Bosulif — Philadelphia chromosome-positive ALL
Prior treatment with at least one other tyrosine kinase inhibitor.
Step
Product/indication
Prior-therapy requirement
1
Bosentan — CTEPH
Try Adempas, have a contraindication to Adempas, or already be receiving bosentan for CTEPH.
Step
Product/indication
Prior-therapy requirement
1
Bosulif — Philadelphia chromosome-positive ALL
Prior treatment with at least one other tyrosine kinase inhibitor.
Step
Product/indication
Prior-therapy requirement
1
Brukinsa
Indication-specific prior systemic regimens or specified combination therapy are required. Follicular lymphoma requires at least two prior systemic regimens; mantle cell, marginal zone, and primary CNS lymphoma generally require at least one.
Step
Product/indication
Prior-therapy requirement
1
Cabometyx
Indication-specific prior therapy is required, including prior systemic therapy for hepatocellular, bone, endometrial, thyroid, GIST, or RET-positive NSCLC indications as specified.
Step
Product/indication
Prior-therapy requirement
1
Calquence
At least one prior systemic regimen for mantle cell lymphoma, marginal zone lymphoma, or Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, unless the stated mantle cell lymphoma exception applies.
Try another therapy, such as systemic corticosteroids, IVIG, anti-D immunoglobulin, eltrombopag, romiplostim, fostamatinib, or rituximab, or undergo splenectomy.
Step
Product/indication
Prior-therapy requirement
1
Dupixent — COPD
Receive at least 3 months of combination therapy with at least two of LAMA, LABA, or ICS before initiation.
Step
Product/indication
Prior-therapy requirement
1
Dupixent — asthma
Use an inhaled corticosteroid with at least one additional asthma controller or maintenance medication.
Step
Product/indication
Prior-therapy requirement
1
Enbrel — initial therapy
For RA, JIA/JRA, ankylosing spondylitis, plaque psoriasis, or psoriatic arthritis, try one preferred or non-preferred adalimumab product. For Behcet disease, try at least one conventional therapy. No stated prerequisite applies for GVHD.
Step
Product/indication
Prior-therapy requirement
1
Epidiolex — initial therapy
Try or concomitantly receive at least two other antiseizure drugs. For Dravet syndrome, Diacomit, clobazam, or Fintepla may alternatively satisfy the requirement.
Step
Product/indication
Prior-therapy requirement
1
Elrexfio — multiple myeloma
Try at least four systemic regimens, including at least one drug from each required prior-treatment class.
Step
Product/indication
Prior-therapy requirement
1
Erivedge — locally advanced basal cell carcinoma, new starts
Recurrent disease after surgery or radiation, or the patient is not a candidate for both surgery and radiation.
Step
Product/indication
Prior-therapy requirement
1
Fintepla — initial therapy
Try or concomitantly receive at least two other antiseizure drugs. For Dravet syndrome, Epidiolex, clobazam, or Diacomit may alternatively satisfy the requirement.
Step
Product/indication
Prior-therapy requirement
1
Fotivda — relapsed or stage IV RCC
At least two prior systemic regimens.
Step
Product/indication
Prior-therapy requirement
1
Fruzaqla — advanced or metastatic colon, rectal, or appendiceal cancer
Prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy plus an anti-VEGF agent; applicable checkpoint-inhibitor pathway requirements also apply.
Prescribing by or consultation with an endocrinologist or a physician specializing in transgender patient treatment.
Step
Product/indication
Prior-therapy requirement
1
Inluriyo — breast cancer
Tried at least one endocrine therapy, such as fulvestrant, anastrozole, exemestane, letrozole, or tamoxifen.
Step
Product/indication
Prior-therapy requirement
1
Inlyta
For differentiated thyroid carcinoma, disease must be refractory to radioactive iodine where applicable; thymic carcinoma requires at least one prior chemotherapy regimen.
Step
Product/indication
Prerequisite requirement
1
Inqovi — AML
Patient is at least 75 years old or has comorbidities precluding intensive induction therapy, and Inqovi is used in combination with Venclexta.
Step
Product/indication
Prior-therapy requirement
1
Jakafi or Jakafi XR
Indication-specific prior treatment may include hydroxyurea, peginterferon alfa-2a, anagrelide, a conventional systemic treatment, a systemic corticosteroid, or other specified therapy.
Step
Product/indication
Prior-therapy requirement
1
Jaypirca
Mantle cell lymphoma requires prior systemic chemotherapy or ineligibility for it plus a prior BTK inhibitor. CLL/SLL requires a prior BTK inhibitor. Richter transformation requires prior chemotherapy or ineligibility for a systemic regimen.
Quantity and Duration Limits
Ivermectin oral tablet quantity limit
MedicationIvermectin oral tablet 3 mg and 6 mg
Coverage duration30 days
Covered conditionsPediculosis and qualifying scabies, including classic, treatment-resistant, crusted, or topical-treatment-intolerant scabies
Prerequisite therapyYes
Preferred Biosimilar Prerequisites
Note
Use a preferred adalimumab product when required
These products are identified as preferred adalimumab products for Enbrel prerequisite therapy. A trial of a non-preferred adalimumab product also counts.
Preferred products: Hadlima and Simlandi.
Policy Summary
PayerCareSource
PolicyActemra intravenous and subcutaneous coverage
Policy CodePolicy 4588458
Change TypeNo material change
Effective DateOctober 1, 2026
Next Review DateN/A
Key ActionSubmit prior authorization for Actemra intravenous, Actemra ACTPEN, or Actemra subcutaneous products and include the diagnosis, concurrent medications, and previous drugs tried.